Cardiovascular Adverse Effects of Common Non-Oncologic Medications: From Mechanisms to Clinical Management [0.03%]
常见非肿瘤药物的心血管不良反应：从机制到临床管理
M Cecilia Bahit,Pilar Agudo-Quilez,Jose Zamorano et al.
M Cecilia Bahit et al.
Cardiovascular adverse effects of drugs has significant practical implications for patient management. While cardiovascular adverse effects have commonly been associated with oncologic therapeutics, a growing body of evidence suggests that ...
Net Clinical Benefit of Extended Dual Pathway Inhibition in Chronic Coronary Syndrome as Classified by the 2024 ESC Criteria: a COMPASS Substudy [0.03%]
根据2024年ESC标准分类的慢性冠状动脉综合征患者中延长双通路抑制的临床净益：来自COMPASS子研究的结果
Morten Würtz,Kevin Kris Warnakula Olesen,Qilong Yi et al.
Morten Würtz et al.
Background and aims: Extended dual pathway inhibition (DPI) with aspirin and rivaroxaban is recommended in high-risk patients with chronic coronary syndrome (CCS). In the 2024 update of the European Society of Cardiology ...
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention [0.03%]
经皮冠状动脉介入术治疗非ST段抬高型急性冠脉综合征时阿司匹林让位其他药物？
Patricia O Guimarães,Caio A M Tavares,Marcelo Franken et al.
Patricia O Guimarães et al.
Cardiac Adverse Events Associated with Dual Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis from the FDA Adverse Event Reporting System [0.03%]
基于美国食品药品监督管理局不良事件报告系统的免疫检查点抑制剂相关心血管不良事件的药物流行病学分析
Huang Xia,Lei Shi,Shuimei Luo et al.
Huang Xia et al.
Background: Immune-related adverse events(irAEs) are common among cancer patients receiving dual immune checkpoint inhibitors (ICI). Cardiac adverse events rank among the most severe categories of such reactions. This stu...
Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial [0.03%]
无射血分数降低的急性及慢性冠脉综合征患者中β受体阻滞剂治疗效果的里程碑式分析——来自REBOOT试验的结果
Xavier Rossello,José A Barrabés,Massimo Piepoli et al.
Xavier Rossello et al.
Background and aims: Current guidelines recommend beta-blocker therapy after myocardial infarction (MI) regardless of left ventricular ejection fraction (LVEF). However, recent trials question their benefit in patients wi...
Withdrawing heart failure therapy after AF rhythm control: promise, caution, and perspective [0.03%]
心力衰竭患者房颤节律控制后撤疗法的希望、谨慎和展望
Felice Gragnano,Vincenzo De Sio,Mattia Galli et al.
Felice Gragnano et al.
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂与应激性心肌病长期生存改善相关：源于大规模真实世界数据的启示
Elias Rawish,Felicitas Lemmer,Katharina Kurz et al.
Elias Rawish et al.
Aims: Takotsubo syndrome (TTS) is an acute cardiac condition marked by transient left ventricular dysfunction. Pharmacological management is largely empirical. SGLT2 inhibitors (SGLT2i) offer cardioprotective effects in o...